Literature DB >> 16785115

The use of botulinum toxins to treat hyperhidrosis and gustatory sweating syndrome.

D A Glaser1.   

Abstract

Hyperhidrosis is a chronic condition characterized by excessive sweating. Recent studies report that it affects approximately 2.8% of the population and typically begins during adolescence. Gustatory sweating usually occurs after parotid gland injury or surgery, and both disorders can be debilitating for those who are affected. Both diseases respond very well to botulinum toxin therapy and this article will review the use of botulinum toxins, including the serotypes used, dosing, and complications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785115     DOI: 10.1007/bf03033936

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  21 in total

1.  Treatment of Frey syndrome with botulinum toxin type F.

Authors:  V Tugnoli; R Marchese Ragona; R Eleopra; D De Grandis; C Montecucco
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2001-03

2.  Systemic adverse effects after botulinum toxin type B (myobloc) injections for the treatment of palmar hyperhidrosis.

Authors:  Leslie S Baumann; Monica L Halem
Journal:  Arch Dermatol       Date:  2003-02

3.  Successful treatment of axillary hyperhidrosis with very low doses of botulinum toxin B: a pilot study.

Authors:  Martin J Hecht; Frank Birklein; Martin Winterholler
Journal:  Arch Dermatol Res       Date:  2003-11-29       Impact factor: 3.017

4.  Botulinum A toxin improves life quality in severe primary focal hyperhidrosis.

Authors:  C Swartling; H Naver; M Lindberg
Journal:  Eur J Neurol       Date:  2001-05       Impact factor: 6.089

5.  Treatment of gustatory sweating with botulinum toxin.

Authors:  M Naumann; M Zellner; K V Toyka; K Reiners
Journal:  Ann Neurol       Date:  1997-12       Impact factor: 10.422

6.  Up-to-date report of botulinum toxin type A treatment in patients with gustatory sweating (Frey's syndrome).

Authors:  R Laskawi; C Drobik; C Schönebeck
Journal:  Laryngoscope       Date:  1998-03       Impact factor: 3.325

7.  Botulinum toxin type A for Frey's syndrome: a preliminary prospective study.

Authors:  O Laccourreye; L Muscatelo; C Naude; B Bonan; D Brasnu
Journal:  Ann Otol Rhinol Laryngol       Date:  1998-01       Impact factor: 1.547

8.  Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial.

Authors:  M K Naumann; H Hamm; N J Lowe
Journal:  Br J Dermatol       Date:  2002-12       Impact factor: 9.302

9.  Botulinum toxin type B for treatment of axillar hyperhidrosis.

Authors:  Dirk Dressler; Fereshte Adib Saberi; Reiner Benecke
Journal:  J Neurol       Date:  2002-12       Impact factor: 4.849

10.  BOTOX delivery by iontophoresis.

Authors:  G M Kavanagh; C Oh; K Shams
Journal:  Br J Dermatol       Date:  2004-11       Impact factor: 9.302

View more
  4 in total

Review 1.  Botulinum neurotoxin: evolution from poison, to research tool--onto medicinal therapeutic and future pharmaceutical panacea.

Authors:  Richard M Kostrzewa; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

2.  Frey syndrome in a patient with facial melanoma: auriculotemporal syndrome presenting with gustatory sweating following wide local excision, sentinel node biopsy, and superficial parotidectomy.

Authors:  Richard R Jahan-Tigh; Philip R Cohen
Journal:  J Clin Aesthet Dermatol       Date:  2012-07

Review 3.  The use of botulinum toxin in head and face medicine: an interdisciplinary field.

Authors:  Rainer Laskawi
Journal:  Head Face Med       Date:  2008-03-10       Impact factor: 2.151

4.  Sustained benefit lasting one year from T4 instead of T3-T4 sympathectomy for isolated axillary hyperhidrosis.

Authors:  Marco Antonio S Munia; Nelson Wolosker; Paulo Kaufmann; José Ribas Milanes de Campos; Pedro Puech-Leão
Journal:  Clinics (Sao Paulo)       Date:  2008-12       Impact factor: 2.365

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.